Loading
Virtual Incision
  • Virtual Incision
    • About
    • Company Values
    • Leadership Team
    • Recent News
      • Newsroom
  • miniRAS
  • MIRA
    • Components
    • Space Age Technology
  • Safety Information
  • Careers
  • Contact
  • Menu Menu

Virtual Incision Explores NVIDIA Isaac for Healthcare in Surgical Robotics

Press Release, Recent News

— New AI-driven simulation platform has the potential to safely and efficiently design, test, and deploy advanced robotic and autonomous systems for healthcare applications. —

LINCOLN, Nebraska – March 18, 2025 – Virtual Incision Corporation, developer of the MIRA Surgical System, has announced plans to explore the use of NVIDIA Isaac for Healthcare in developing their next-generation surgical robotics platforms. Digital twin framework capabilities integrated with robotic learning tools will enable Virtual Incision’s developers to create highly realistic virtual environments to simulate surgical details and physiologic processes. Virtual Incision also continues to explore the NVIDIA Cosmos platform for the development of future surgical robots. The goal is to accelerate the product development cycle by leveraging comprehensive testing throughout digital prototyping, simulation, and physical deployment.

"Developing a surgical robot is a rigorous process, and great care must be taken to ensure that the product is safe, smart, and effective,” said John Murphy, chief executive officer of Virtual Incision. “As we work on future iterations of MIRA, we’re excited to use NVIDIA Isaac for Healthcare to bring our surgeons and patients the most advanced technologies safely and expeditiously.”

About the MIRA Surgical System

MIRA is the world’s first miniaturized robotic-assisted surgery (RAS) system. Its small, sleek form factor is designed to offer the benefits of RAS during colectomy procedures without the logistical inefficiencies of traditional mainframe robotics. The easily accessible device weighs approximately two pounds (less than one kg) and offers internal triangulation with shoulders, arms, and infinite wrist roll inside of the body. It can be used in any operating room – a dedicated mainframe room is unnecessary. With its drape- and dock-free design and portability, MIRA is quick to set up, clean up, and move between cases. Its conveniently accessible design positions it to be used as a standalone system or a complementary tool for facilities that already own a mainframe. With MIRA, every operating room is RAS-ready.

About Virtual Incision

Virtual Incision is on a mission to simplify robotic-assisted surgery (RAS), so more patients and their surgeons can access its benefits every day. Headquartered in Lincoln, Nebraska, and holding over two hundred patents and patent applications, the company developed MIRA, the first-of-its-kind miniature RAS system. Virtual Incision’s goal is to make every operating room RAS-ready. For more information, visit our website or follow us on LinkedIn and X.

Important Safety Information

The MIRA Surgical System is intended for prescription use only. Patients should talk to their doctor to decide if surgery with a MIRA Surgical System is right for them. For important safety information, indications for use, risks, and warnings, please refer to www.virtualincision.com/safety-information. All remote surgical procedures using a modified version of the MIRA Surgical System are for demonstration purposes only and have not been evaluated by the U.S. Food and Drug Administration.

Cautionary Note Regarding Forward-Looking Statements

This communication contains statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include but are not limited to, statements regarding our plans, beliefs, expectations, assumptions, and other statements that are not necessarily historical facts. You are cautioned that these forward-looking statements are only predictions and involve risks and uncertainties. Further, any forward-looking statement speaks only as of the date on which it is made, and we do not intend to update or revise any forward-looking statements. This communication also contains market data related to our business and industry which includes projections that are based on several assumptions we believe are reasonable and most significant to the projections as of the date of this communication. If any of our assumptions prove to be incorrect, our actual results may significantly differ from our projections based on these assumptions.

Media Contact:

Ashlynn Meyer

Virtual Incision

ashlynn.meyer@virtualincision.com

https://virtualincision.com/wp-content/uploads/2024/03/323829966.jpg 400 400 ashlynn meyer /wp-content/uploads/2022/08/logo-mrk-wht.svg ashlynn meyer2025-03-18 13:02:302025-03-18 13:09:56Virtual Incision Explores NVIDIA Isaac for Healthcare in Surgical Robotics

U.S.-Based Remote Robotic-Assisted Surgery Demonstration Successfully Completed Through Collaborations with Virtual Incision, Sovato, City of Hope, and University of Illinois Chicago

Press Release, Recent News

— Wet lab demonstration showcases the safe enablement, reproducibility, and scale of remote robotic-assisted surgeries across twenty procedures and four specialties —

— Initial preclinical data presented at the 15th Clinical Robotic Surgery Association’s Worldwide Congress —

LINCOLN, Nebraska – November 25, 2024 – Virtual Incision Corporation, the developer of the MIRA Surgical System (MIRA), the world’s first miniaturized robotic-assisted surgery (RAS) device and Sovato Health, the world’s only comprehensive solution designed to enable remote surgery and procedure programs, today announced the successful completion of a preclinical demonstration of nearly 40,000-miles combined distance. Four surgeons performed a total of 20 procedures on porcine models as part of the remote capabilities test, representing approximately 2,000 miles for each procedure.

Francesco Maria Bianco, M.D. from the University of Illinois Chicago, and Yanghee Woo, M.D., Yasmin Zerhouni, M.D., and Clayton Lau, M.D., from City of Hope National Medical Center, which is ranked among the nation’s top 5 cancer centers by U.S. News & World Report, leveraged the combined technology of Virtual Incision and Sovato to complete the remote cholecystectomy, colectomy, gastric mobilization / gastrostomy / primary closure, and nephrectomy procedures on porcine models. Yuman Fong, M.D., chair and professor of City of Hope’s Department of Surgery and president-elect of Clinical Robotic Surgery Association (CRSA), oversaw the design and completion of the wet lab demonstrations.

The Sovato Platform provided the surgical-grade network connectivity between the physicians’ location in Santa Barbara, CA, and the porcine models in Chicago, IL, as well as clinical workflows and immersive audio-visuals for intraoperative communication. The results demonstrate the safe enablement of surgery at a distance for a variety of complex and routine surgical procedures and the unique benefits miniaturization offers in expanding access to robotic-assisted surgery.

Remote surgery will help address the needs of more than half the world’s population that does not currently have access to high-quality surgical care, including 83 million Americans who must travel for routine procedures.1 Robotic-assisted technologies have the potential to enable minimally invasive surgery for these patients by allowing a surgeon to operate from a distant location. MIRA, the first miniaturized robotic-assisted surgery (miniRAS) device in development, is roughly 1,000 times lighter than existing RAS technologies. As the only small form factor RAS device, it has the potential to make remote surgery more feasible by enabling transportation, storage, and setup time at locations where robotics is not currently available.

“Virtual Incision’s vision is that miniaturization could make robotic-assisted surgery available to any patient, anytime, anywhere, and we believe this could potentially extend even further with the possibility of remote surgery,” said Piet Hinoul, M.D., Ph.D., chief medical officer at Virtual Incision. “This experiment demonstrates the usability and reproducibility across multiple specialties, even when operating from a distance. We look forward to continuing to assess MIRA for use across a broad range of procedures and are eager to extend upon the benefits miniaturization brings.”

As the remote-enabling technology, Sovato provided stable network connectivity, with low latency of less than 60 milliseconds and 0% packet loss, enabling clear person-to-person communication and effective completion of the procedures, in addition to a user-reported intraoperative experience comparable to performing remote procedures in person.

“These wet lab results provide evidence that by connecting the people, devices, and information systems required for remote surgery, the Sovato Platform restores situational awareness and provides clear person-to-person communication for all the caregivers participating in remote procedures,” said Dennis Fowler, MD, MPH, chief medical officer at Sovato. “We are thrilled by the ongoing success of these demonstrations and the continued confidence and enthusiasm the surgeons have toward remote capabilities.”

“The successful completion of these remote robotic-assisted procedures with miniaturized robotics proves we are close to enabling unprecedented access to best-in-class surgical care,” Dr. Fong said. “Remote surgery will allow a surgeon sitting in one location to help patients in many locations – in different cities, states, or even countries. Remote capabilities will extend surgical expertise, enhance training opportunities, and provide access to high-quality surgical care like never before. City of Hope is proud to lead this encouraging step forward in clinical robotics that could become the future of our surgical industry, and most importantly, we are proud of the access this technology will provide, where patients anywhere can be operated on by specialized cancer surgeons like those at City of Hope.”

About the MIRA Surgical System

MIRA is the world’s first miniaturized robotic-assisted surgery (RAS) system. Its small, sleek form factor is designed to offer the benefits of RAS during colectomy procedures without the logistical inefficiencies of traditional mainframe robotics. The easily accessible device weighs approximately two pounds (less than one kg) and offers internal triangulation with shoulders, arms, and infinite wrist roll inside of the body. It can be used in any operating room – a dedicated mainframe room is unnecessary. With its drape- and dock-free design and portability, MIRA is quick to set up, clean up, and move between cases. Its conveniently accessible design positions it to be used as a standalone system or a complementary tool for facilities that already own a mainframe. With MIRA, every operating room is RAS-ready.

About Virtual Incision

Virtual Incision is on a mission to simplify robotic-assisted surgery (RAS), so more patients and their surgeons can access its benefits every day. Headquartered in Lincoln, Nebraska, and holding over two hundred patents and patent applications, the company developed MIRA, the first-of-its-kind miniature RAS system. Virtual Incision’s goal is to make every operating room RAS-ready. For more information, visit our website or follow us on LinkedIn and X.

Important Safety Information

The MIRA Surgical System is intended for prescription use only. Patients should talk to their doctor to decide if surgery with a MIRA Surgical System is right for them. For important safety information, indications for use, risks, and warnings, please refer to www.virtualincision.com/safety-information. All remote surgical procedures using a modified version of the MIRA Surgical System are for demonstration purposes only and have not been evaluated by the U.S. Food and Drug Administration.

About Sovato

Sovato is creating unprecedented access to high-quality surgical care by enabling and orchestrating safe, scalable, and profitable remote robotic-assisted surgery and procedure programs that span the entire surgical journey. Sovato is the world’s first and only robotagnostic platform enabling remote surgery and procedure programs for healthcare organizations at a global scale. Based in Santa Barbara, CA, the company is co-founded by Cynthia Perazzo, MBA, and industry pioneer Yulun Wang, PhD, the founder of Computer Motion (merged with Intuitive Surgical) and InTouch Health (acquired by Teladoc Health). For more information, visit www.Sovato.com or follow company updates on LinkedIn.

The Sovato Platform has not been evaluated by the U.S. Food and Drug Administration and is not currently available for sale in the U.S.

Cautionary Note Regarding Forward-Looking Statements

This communication contains statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include but are not limited to, statements regarding our plans, beliefs, expectations, assumptions, and other statements that are not necessarily historical facts. You are cautioned that these forward-looking statements are only predictions and involve risks and uncertainties. Further, any forward-looking statement speaks only as of the date on which it is made, and we do not intend to update or revise any forward-looking statements. This communication also contains market data related to our business and industry which includes projections that are based on several assumptions we believe are reasonable and most significant to the projections as of the date of this communication. If any of our assumptions prove to be incorrect, our actual results may significantly differ from our projections based on these assumptions.

References:

  1. https://jamanetwork.com/journals/jamasurgery/article-abstract/2796554

Media Contact:

Erin Crowley

Health+Commerce

erin@healthandcommerce.com

https://virtualincision.com/wp-content/uploads/2024/11/©2024_SOVATO_ChristianLee-18-scaled.jpg 2560 1707 ashlynn meyer /wp-content/uploads/2022/08/logo-mrk-wht.svg ashlynn meyer2024-11-25 05:30:592024-11-25 05:30:59U.S.-Based Remote Robotic-Assisted Surgery Demonstration Successfully Completed Through Collaborations with Virtual Incision, Sovato, City of Hope, and University of Illinois Chicago

Virtual Incision Announces Successful Completion of the First Hysterectomy Performed with the MIRA™ Surgical System

Press Release, Recent News

Clinical study results intended to be used in regulatory submissions for gynecologic indications

New study begins on the heels of FDA marketing authorization for use in adults undergoing colectomy procedures

LINCOLN, Nebraska – July 30, 2024 – Virtual Incision Corporation, the developer of the MIRA Surgical System (MIRA), today announced the successful completion of the first surgery in a clinical study assessing the safety and efficacy of its miniaturized robotic-assisted surgery (miniRAS) device in benign hysterectomy procedures.

More than one million women in the U.S. alone undergo surgery for benign gynecologic conditions annually.1 A minimally invasive approach can shorten the hospital stay, reduce blood loss and decrease complication rates compared to open surgery. Robotic-assisted surgery (RAS) devices, like MIRA, could elevate the surgeon’s vision, precision, and control when operating through a small incision, ultimately enabling the techniques to be performed on a broader range of patients.2 However, about 90 percent of U.S. operating rooms (ORs) are still lacking access to RAS, most often due to complex logistics such as dedicated space, specially trained staff, long turnover times and a substantial cost for the equipment.3.

MIRA’s innovative tray-to-table design could offer healthcare facilities the advantages of RAS without requiring them to organize the OR around the device. The miniRAS device’s compact, approximately two-pound (less than one kg), framework is portable and designed to make any OR robot-ready within minutes.

The MIRA Surgical System Hysterectomy Study is an international prospective clinical study designed to evaluate device performance and safety of the MIRA Surgical System when used to robotically assist in benign hysterectomy procedures. Outcomes from this study are planned to support future U.S. and international regulatory submissions for benign gynecologic indications. This study is the second clinical study of MIRA. The first study, under a U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE) protocol, supported the De Novo marketing authorization for MIRA in colectomy procedures that was announced in February 2024.

This first surgery was successfully completed at the Geneva University Hospitals by Jean Dubuisson, M.D., Ph.D., a gynecologic surgeon and the principal investigator for the MIRA Surgical System Hysterectomy Study.

“Completing the first hysterectomy with the MIRA Surgical System is an exciting milestone for our hospital and for the entire field of gynecology,” said Dr. Dubuisson. “Robotic-assisted surgery is a valuable tool, but technology access is still a challenge due to cost, time and operating room space. Miniaturization has the potential to overcome these issues and enable more women to have a minimally invasive option for their surgery. We are pleased with the results so far and look forward to further assessing the device in the MIRA Hysterectomy Study.”

“At Virtual Incision, we are anchored in clinical excellence as our first priority,” said Piet Hinoul M.D., Ph.D., chief medical officer of Virtual Incision. “We are encouraged by the results of our clinical and preclinical work to date, and we believe that miniaturized robotic-assisted surgery will have broad applications across a wide variety of procedures. We are grateful to the Geneva University Hospital team for their contributions, as well as to the patients who are willing to participate in this important work. We are excited to reach this milestone as part of our mission to make every operating room robot-ready.

In parallel to conducting the MIRA Surgical System Hysterectomy Study, Virtual Incision is continuing to innovate in the field of miniaturized surgical robotics. New iterations are in design that will enable MIRA to be applied across specialties including general surgery, urology, and other soft tissue and solid organ surgery.

About the MIRA Surgical System

MIRA is the world’s first miniaturized robotic-assisted surgery (RAS) system. Its small, sleek form factor is designed to offer the benefits of RAS during colectomy procedures without the logistical inefficiencies of traditional mainframe robotics. The easily accessible device weighs approximately two pounds (less than one kg) and offers internal triangulation with shoulders, arms, and infinite wrist roll inside of the body. It can be used in any operating room – a dedicated mainframe room is unnecessary. With its drape- and dock-free design and portability, MIRA is quick to set up, clean up, and move between cases. Its conveniently accessible design positions it to be used as a standalone system or a complementary tool for facilities that already own a mainframe. With MIRA, every operating room is RAS-ready.

About Virtual Incision

Virtual Incision is on a mission to simplify robotic-assisted surgery (RAS), so more patients and their surgeons can access its benefits every day. Headquartered in Lincoln, Nebraska, and holding over two hundred patents and patent applications, the company developed MIRA, the first-of-its-kind miniature RAS system. Virtual Incision’s goal is to make every operating room RAS-ready. For more information, visit our website or follow us on LinkedIn and X.

Important Safety Information

The MIRA Surgical System is intended for prescription use only. Patients should talk to their doctor to decide if surgery with a MIRA Surgical System is right for them. For important safety information, indications for use, risks, and warnings, please refer to www.virtualincision.com/safety-information.

Cautionary Note Regarding Forward-Looking Statements

This communication contains statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include but are not limited to, statements regarding our plans, beliefs, expectations, assumptions, and other statements that are not necessarily historical facts. You are cautioned that these forward-looking statements are only predictions and involve risks and uncertainties. Further, any forward-looking statement speaks only as of the date on which it is made, and we do not intend to update or revise any forward-looking statements. This communication also contains market data related to our business and industry which includes projections that are based on several assumptions we believe are reasonable and most significant to the projections as of the date of this communication. If any of our assumptions prove to be incorrect, our actual results may significantly differ from our projections based on these assumptions.

References:

  1. Life Science Intelligence 2021 Report on Obstetrics and Gynecology.
  2. Lenfant L, Canlorbe G, Belghiti J, Kreaden US, Hebert AE, Nikpayam M, Uzan C, Azaïs H. Robotic-assisted benign hysterectomy compared with laparoscopic, vaginal, and open surgery: a systematic review and meta-analysis. J Robot Surg. 2023 Dec;17(6):2647–2662. doi: 10.1007/s11701-023–01724‑6. Epub 2023 Oct 19. PMID: 37856058; PMCID: PMC10678826.
  3. Hazan, A., Perse, J., Coover, P. June 2022. State of the Robotics Surgery Market. Goldman Sachs.

Media Contact:

Jenna Kane

Health+Commerce

jennakane@healthandcommerce.com

(480) 388‑9587

# # #

https://virtualincision.com/wp-content/uploads/2024/07/MIRAFeaturedImage-2.png 2163 2128 ashlynn meyer /wp-content/uploads/2022/08/logo-mrk-wht.svg ashlynn meyer2024-07-30 05:00:182024-07-30 05:00:18Virtual Incision Announces Successful Completion of the First Hysterectomy Performed with the MIRA™ Surgical System

Virtual Incision Announces Publication of Data from its U.S. Investigational Device Exemption Study in the Clinical Journal, Diseases of Colon and Rectum

Press Release, Recent News

 – Data demonstrate the safety and efficacy of the MIRA Surgical System, a novel miniaturized robotic-assisted surgery device, in adults undergoing colectomy procedures

LINCOLN, Neb. – April 30, 2024 – Virtual Incision Corporation, the developer of the MIRA™ Surgical System (MIRA), today announced data from its Investigational Device Exemption (IDE) clinical study has been published in Diseases of Colon and Rectum. The study was designed to assess the safety and efficacy of MIRA, the world’s first miniaturized robotic-assisted surgery device, in adults undergoing colectomy procedures. Results were provided to the Food and Drug Administration (FDA) as part of the submission to support the de novo marketing authorization of the device.

The data demonstrated the following results:

  • The primary efficacy endpoint, the successful completion of pre-defined procedural steps without conversion to open surgery, was met.
  • The primary safety endpoints, overall intraoperative and postoperative adverse events (AEs), and the incidence of serious AEs (device and procedure-related) were also met. There were no intraoperative surgical complications.

“There is a growing body of clinical evidence that suggests short-term outcomes, complications, and quality of life are all improved following a minimally invasive approach for colon surgery,” said John H. Marks, MD, FACS, FASCRS, director of the Colorectal Center at Lankenau Medical Center, chief of the section of colorectal surgery at Main Line Healthcare, and an investigator for the study. “Utilization of robotic-assisted surgery for colectomy procedures is growing and these results suggest that miniaturized robotic-assisted surgery devices can be successfully used in these complex procedures. We’re excited to continue to build upon data supporting the use of miniRAS and look forward to learning more about the potential positive impact on patient and health economic outcomes.”

“The publication of the IDE study data in Diseases of Colon and Rectum marks a key milestone for MIRA as an evidence-based option for surgeons seeking safe and effective outcomes for patients following colectomies,” said Piet Hinoul, MD, PhD, chief medical officer of Virtual Incision. “We look forward to further assessing this miniRAS device for a wide range of procedures and are eager to bring the benefits of robotic-assisted surgery to more patients across the globe.”

About Virtual Incision

Virtual Incision is on a mission to simplify robotic-assisted surgery (RAS), so more patients and their surgeons can access its benefits every day. Headquartered in Lincoln, Nebraska, and holding over two hundred patents and patent applications, the company developed MIRA, the first-of-its-kind miniature RAS system. Virtual Incision’s goal is to make every operating room RAS-ready. For more information, visit our website or follow us on LinkedIn and X.

About the MIRA Surgical System

MIRA is the world’s first miniaturized robotic-assisted surgery (RAS) system. Its small, sleek form factor is designed to offer the benefits of RAS during colectomy procedures without the logistical inefficiencies of traditional mainframe robotics. The easily accessible device weighs approximately two pounds (less than one kg) and offers internal triangulation with shoulders, arms, and infinite wrist roll inside of the body. It can be used in any operating room – a dedicated mainframe room is unnecessary. With its drape- and dock-free design and portability, MIRA is quick to set up, clean up, and move between cases. Its conveniently accessible design positions it to be used as a standalone system or a complementary tool for facilities that already own a mainframe. With MIRA, every operating room is RAS-ready.

Important Safety Information

The MIRA Surgical System is intended for prescription use only. Patients should talk to their doctor to decide if surgery with a MIRA Surgical System is right for them. For important safety information, indications for use, risks, and warnings, please refer to www.virtualincision.com/safety-information.

Cautionary Note Regarding Forward-Looking Statements

This communication contains statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include but are not limited to, statements regarding our plans, beliefs, expectations, assumptions, and other statements that are not necessarily historical facts. You are cautioned that these forward-looking statements are only predictions and involve risks and uncertainties. Further, any forward-looking statement speaks only as of the date on which it is made, and we do not intend to update or revise any forward-looking statements. This communication also contains market data related to our business and industry which includes projections that are based on several assumptions we believe are reasonable and most significant to the projections as of the date of this communication. If any of our assumptions prove to be incorrect, our actual results may significantly differ from our projections based on these assumptions.

Media Contact:

Jenna Kane

Health+Commerce

jennakane@healthandcommerce.com

(480) 388‑9587

https://virtualincision.com/wp-content/uploads/2023/10/VIC-PS-6495-Mobile-HP-Hero.jpg 2162 2127 jeremiah /wp-content/uploads/2022/08/logo-mrk-wht.svg jeremiah2024-04-30 06:57:022024-04-30 06:57:57Virtual Incision Announces Publication of Data from its U.S. Investigational Device Exemption Study in the Clinical Journal, Diseases of Colon and Rectum

Surgery in space: Tiny remotely operated robot completes first simulated procedure at the space station

Recent News
https://virtualincision.com/wp-content/uploads/2024/02/240213193108-surgical-robot-in-space-pkg.jpeg 450 800 jeremiah /wp-content/uploads/2022/08/logo-mrk-wht.svg jeremiah2024-02-13 07:14:562024-02-24 07:40:03Surgery in space: Tiny remotely operated robot completes first simulated procedure at the space station

Pages

  • Careers
  • CHART
  • Chris O’Hara
  • Confirmation
  • Contact Information
  • Crystal Simon PhD
  • Device Talks 2024 Presentation
  • Dmitry Oleynikov MD, FACS
  • Email list
  • Erik's Playground
  • Florence Beck MS
  • Jessie Snover
  • John Murphy MBA, MS
  • Media Contact
  • miniRAS
  • MIRA
  • Mukund Srinivasan PhD, MBA
  • Newsroom
  • Piet Hinoul, MD, PhD
  • Privacy Policy
  • Quick Links
  • Rick Schefelker
  • Rob Laird
  • Safety Information
  • Schedule a demo of MIRA
  • Shane Farritor PhD, MS
  • Surgeons
  • Terms of Use
  • Testing Mailchimp Form
  • Virtual Incision
  • Visitor Popup

Categories

  • Press Release
  • Recent News

Archive

  • March 2025
  • November 2024
  • July 2024
  • April 2024
  • March 2024
  • February 2024
  • January 2024
  • September 2023
  • May 2023
  • March 2023
  • February 2023

Disclosure and Important Safety Information

The MIRA Surgical System is intended for prescription use only. Patients should talk to their doctor to decide if surgery with a MIRA Surgical System is right for them. Patients and doctors should review all available information on nonsurgical and surgical options and associated risks in order to make an informed decision.

Serious complications may occur in any surgery, including minimally invasive surgery with the MIRA Surgical System, up to and including death. Serious risks include, but are not limited to, injury to tissues and organs, and/or conversion to other surgical techniques which could result in a longer operative time and/or complications.

For important safety information, including surgical risks and considerations, please also refer to www.virtualincision.com/safety-information. For the product’s indications for use, risks, full cautions, and warnings, please refer to the associated user manual(s).

Individual outcomes may depend on a number of factors, including but not limited to patient characteristics, disease characteristics, surgeon, and/or hospital experience.

MIRA Surgical System Precaution Statement

The demonstration of safety and effectiveness for the representative specific procedures was based on evaluation of the MIRA Surgical System as a surgical device and did not include evaluation of outcomes related to the treatment of cancer (overall survival, disease-free survival, local recurrence) or treatment of the patient’s underlying disease/condition. Device usage in all surgical procedures should be guided by the clinical judgment of an adequately trained surgeon.

Contact

Virtual Incision
1501 Old Cheney Rd
Lincoln, NE 68512

  • Privacy Policy
  • Terms of Use
  • @virtualincision
  • @MIRA_by_VIC
  • VirtualIncisionCorporation
  • Virtual Incision media contact
  • Opportunities with Virtual Incision

Sign up today to be the first to get Virtual Incision news and updates

SIGN UP
Back to Top
2024 © Copyright - Virtual Incision®
Scroll to top

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.

Accept settingsHide notification onlySettings

Cookie and Privacy Settings



How we use cookies

We may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.

Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to deliver the website, refuseing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.

We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.

We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.

Google Analytics Cookies

These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.

If you do not want that we track your visit to our site you can disable tracking in your browser here:

Other external services

We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.

Google Webfont Settings:

Google Map Settings:

Google reCaptcha Settings:

Vimeo and Youtube video embeds:

Privacy Policy

You can read about our cookies and privacy settings in detail on our Privacy Policy Page.

Privacy Policy
Accept settingsHide notification only